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Abstract
The potential use of variola virus, the causative agent of smallpox, as a bioweapon and the endemic
presence of monkeypox virus in Africa demonstrate the need for better therapies for
orthopoxvirus infections. Chemotherapeutic approaches to control viral infections have been less
successful than those targeting bacterial infections. While bacteria commonly reproduce
themselves outside of cells and have metabolic functions against which antibiotics can be directed,
viruses replicate in the host cells using the cells' metabolic pathways. This makes it very difficult to
selectively target the virus without damaging the host. Therefore, the development of antiviral
drugs against poxviruses has initially focused on unique properties of the viral replication cycle or
of viral proteins that can be selectively targeted. However, recent advances in molecular biology
have provided insights into host factors that represent novel drug targets. The latest anti-poxvirus
drugs are kinase inhibitors, which were originally developed to treat cancer progression but in
addition block egress of poxviruses from infected cells. This review will summarize the current
understanding of anti-poxvirus drugs and will give an overview of the development of the latest
second generation poxvirus drugs.
Background
The worldwide eradication of the naturally occurring
smallpox virus, variola, in 1980 resulted in a decreased
demand for the development of therapies [1]. Due to
recent worldwide political developments, variola is now-
adays widely regarded as one of the most significant bio-
terrorist threats, reestablishing the need for efficient
therapy for poxvirus infection [2,3]. The impact of a
smallpox virus attack in the human population today
would be even more catastrophic than during the last cen-
tury, since the vaccination programs were suspended
worldwide around 1976 [4]. The lethality of the disease
(up to 40%) and its ease of transmissibility have
prompted the CDC (Center for Disease Control and Pre-
vention), an agency recognized as the leading United
States government agency for protecting public health and
safety, to place variola virus at the top of the high-threat
(Category A) agents list [5]. In addition to the bioweapon
threat, there is a natural public threat arising from mon-
keypox virus, a virus that produces a disease in man that
closely resembles smallpox. Monkeypox exists naturally
in western and central Africa, but 72 cases were also
reported in the United States in 2003 [2,6,7].
Variola and monkeypox viruses belong to the family of
poxviridae, which consists of a collection of large, envel-
oped, double-stranded DNA viruses that are distinguisha-
ble by their unique morphology and cytoplasmic site of
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replication [8]. Poxviruses infect most vertebrates and
invertebrates, causing a variety of diseases of veterinary
and human medical importance. The poxvirus family is
divided into two main subfamilies, the chordopoxvirinae,
which infect vertebrates, and the entomopoxvirinae, which
infect insects. Chordopoxvirinae  are further divided into
eight genera. One of these is orthopoxvirus, which
includes the human pathogens variola virus and monkey-
pox virus, and others which infect humans, including
cowpox and vaccinia virus (VACV). There are at least two
natural strains of variola virus: variola major with a case
fatality rate of 30–40% and variola minor, with a much
reduced fatality rate of approximately 1%.
Poxviruses enter the oropharyngeal and respiratory
mucosa, and proliferate in the regional lymph nodes,
multiplying in particular in the reticulo-endothelial sys-
tem. However, the cellular entry mechanism is unknown
in terms of fusion proteins and cell receptors [9,10].
The 191 kbp VACV DNA genome encodes at least 263
gene products. Their expression is regulated in a temporal
fashion during the viral replication cycle, which begins
with entry of the virus into the host cell and terminates
with the assembly of complex macromolecular structures
to form an infectious particle [11]. Although the molecu-
lar details of poxvirus assembly and differentiation
remain controversial, the most widely accepted scenario
involves the generation of at least three forms of infec-
tious particles (Figure 1). The nomenclature used in this
review follows a recent proposal by Moss [9]. The multiple
infectious forms differ from one another by their outer
membrane. Directly after the attachment and fusion of the
virus with the host cell, the virus is uncoated and the early
gene expression is initiated. At this point, the DNA repli-
cation occurs and is followed by intermediate and late
gene expression. After viral DNA replication, progeny
DNA molecules, virion enzymes and structural proteins
assemble to form the pre-virion particles now referred to
as mature virion (MV). MVs are the simplest and most
abundant form and have no additional membranes and
have previously been called the intracellular mature virion
(IMV). MVs then acquire membranes, whether this is one
or two membranes remains controversial; however, the
current perception prefers the single membrane model
[9]. A portion of the MV then become enveloped with
additional membranes derived from the trans-Golgi appa-
ratus [12,13] or endosomal cisterna [14]. This MV form,
which is surrounded by two membranes, is referred to as
a wrapped virion (WV) [9] instead of the previous intrac-
ellular enveloped virion (IEV), as the MV is already envel-
oped. Following migration to the cell surface, the outer
WV membrane fuses with the plasma membrane resulting
in exocytosis, which gives rise to extracellular enveloped
virus (EV) [15]. The EV can either remain associated with
the cell (formerly CEV = cell-associated virus) or become
unattached and released as extracellular enveloped virus
(EEV) [16]. The associated form is usually predominant
and primarily responsible for cell-to-cell spread via actin
tails [17,18]. Figure 1 shows a schematic view of the VACV
replication cycle and the different virion forms.
Among the approximately 200 genes encoded by variola
virus are many that code for gene products that are needed
for cytoplasmic transcription and replication of the virus.
Therefore, strategies which block such key enzymes in the
replication and maturation of poxviruses provide poten-
tial targets for therapeutic intervention.
Animal models
Animal models that are predictive for human disease out-
come are an important component of drug development.
There are a number of models in use, but none of them
captures all aspects of the human orthopoxvirus infec-
tions. The most relevant are models in which poxvirus
replication is initiated in the periphery and followed by
systemic virus spread, as occurs during variola virus infec-
tions in humans.
A frequently used, straightforward model is the intranasal
VACV infection of mice. It results in local replication and
systemic disease; however, a large inoculation dose needs
to be applied [19]. Ectromelia virus infection of mice
strongly resembles the pathogenicity of human smallpox,
although the time course of infection and disease progres-
sion is much shorter [20]. The parameter that is moni-
tored in both models is disease progression and the
primary end-point is mortality.
Monkeypox virus infections of nonhuman primates have
also been used to evaluate the efficacy of smallpox vac-
cines. A major drawback of these models is the intrave-
nous administration, which bypasses the mucosa and
produces a lesional disease characteristic of post second-
ary viremia. However, disease progression can be moni-
tored more precisely and virus yields can be measured in
serum and by quantifying lesion numbers [21].
Prevention of clinical symptoms: First therapeutic 
approaches towards a treatment of poxvirus infection
From about 2000 BC onwards, treatment of smallpox
infections basically involved prevention of clinical symp-
toms, as no curative therapy was available. Early attempts
to control smallpox began in ancient Egypt through intra-
nasal insufflations of dried crusts of smallpox lesions. In
18th century Europe, the method consisted of subcutane-
ous injection of fluid from smallpox pustules or scabs.
This practice, known as variolization, caused severe cases
of smallpox in about 1 in 200 inoculations. However theVirology Journal 2007, 4:8 http://www.virologyj.com/content/4/1/8
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fatality rate in variolated individuals was considerably
lower than in those who got naturally infected.
The breakthrough in prevention began in the 18th century,
when doctors observed that milkmaids who had con-
tracted cowpox were resistant to infection with smallpox.
Edward Jenner reasoned and finally showed in 1796 that
infectious material from cowpox lesions provided protec-
tion from smallpox. The term vaccination was coined in
1803 from the Latin word for cow (vacca) [22]. Based on
these findings, the World Health Organization undertook
a global smallpox vaccination program in 1967. At that
time, 10 to 15 million cases of the disease occurred each
year with more than 2 million deaths. VACV, a related but
relatively nonpathogenic poxvirus was administered
throughout the world, and this practice resulted in the
eradication of smallpox [1]. When the vaccine, live VACV,
is inoculated into the superficial layers of the skin (skin
scarification), the virus grows locally and induces an
immune reaction that protects against smallpox [23]. This
program of intensively vaccinating all humans in a ring
surrounding every suspected case of variola infection was
successful in part because smallpox is a human-only dis-
ease. There are no animal reservoirs to reintroduce the
virus into the human population. The last occurrence of
endemic smallpox was in Somalia in 1977, and the last
human cases were laboratory-acquired infections in 1978
[24].
Treatment of acute infections
Vaccination programs were suspended worldwide in 1976
and the human population now lacks immunity against
poxviruses, making them attractive as bioweapons. Com-
plications associated with VACV vaccination, which might
occur in immune-compromised individuals, also increase
the demand for drugs that can be used to treat acute infec-
tions. The principles of treatment can be summarized as
follows: Passive immunization, antiviral small molecule
Schematic overview of the VACV replication cycle, the different virion forms and the point of action of anti-poxvirus drugs Figure 1
Schematic overview of the VACV replication cycle, the different virion forms and the point of action of anti-poxvirus drugs.
Attachment & Fusion
EV
(EEV)
Uncoating
Intermediate GE
Late GE
Virion Assembly
MV
(IMV)
Nucleus and ER
Wrapping
WV
(IEV)
cell accosiated EV
(CEV)
unattached EV
(EEV)
VIG
Early GE DNA-Replication
Cidofovir
Rifampin
Protease
Inhibitors
ST-246
CI-1033
Gleevec
Ribavirin
cell accosiated EV
(CEV)Virology Journal 2007, 4:8 http://www.virologyj.com/content/4/1/8
Page 4 of 7
(page number not for citation purposes)
drugs that were identified by random screens and inhibit
viral replication and drugs that target systemic spread of
poxviruses.
Passive Immunization
Passive immunization is one method to treat variola-
infected individuals. In this procedure, antibodies
obtained from the plasma of repeatedly actively vacci-
nated individuals are infused into infected individuals or
those with a high risk of becoming infected. The antibod-
ies provide protection against disease for two to three
weeks, as this is the time they remain active in the body.
Although short-lived, passive immunization provides
immediate protection, unlike active immunization, which
can take weeks to develop. Consequently, passive immu-
nization can be lifesaving when a person has been
infected [25].
The development of humanized monoclonal antibodies
against neutralizing epitopes that are conserved between
monkeypox and variola viruses are therefore promising
advanced tools for passive immunization against poxvi-
ruses. However, a safe, orally active antiviral drug for the
prevention or treatment of smallpox infection is needed
to provide an alternative to the elaborate antibody-based
passive immunization. It has been shown recently that
antiviral treatment is more effective than smallpox vacci-
nation upon lethal intratracheal infection of cynomolgus
monkeys (Macaca fascilaris) with monkeypox virus [26].
Today, there are no FDA-approved drugs available for the
treatment of smallpox; however, there are drugs in early
preclinical development and approved drugs with off-tar-
get effects. All drugs discussed below, and their point of
attack in the viral lifecycle, are summarized in Figure 1.
Small molecule drugs that inhibit viral replication
The search for antiviral agents acting against poxviruses,
without knowing their mode of action, started when the
thiosemicarbazones, introduced in 1946 by Domagk et al.
[27] as tuberculostatic (antituberculous) agents, were also
found to be active against VACV [28]. Hamre et al. found
that the drug was able to reduce infectivity in eggs and
mice by up to 70%. The observation that benzaldehyde
thiosemicarbazone did not inactivate vaccinina virus in
vitro proved that the antiviral effect of this drug was intra-
cellular. This important work was continued by Bauer [29]
and culminated in the demonstration by Bauer et al. [30]
in 1963 that the thiosemicarbazone derivative methia-
zone (Marboran, N-methylisatin 3-thiosemicarbazone)
was effective in the prophylaxis of smallpox. Methiazone
was first applied in 1962 to a smallpox-infected patient
who suffered from infantile eczema and did not respond
to treatment with anti-vaccinia gamma globulin [31]. The
boy showed rapid recovery after treatment and was the
first illustration of the use of an antiviral drug in man [32].
From then on trials with methiazone showed that the
drug not only had an antiviral effect in infected patients
but was also effective as a prophylaxis of smallpox. Prom-
ising results have also been reported in the treatment of
complications of smallpox vaccination. The principal side
effect of severe vomiting was considered a justifiable risk
at the time [33], but is unacceptable for today's use.
Another approved drug is rifampin, which is still one of
the most effective tuberculostatic drugs today. It inhibits
the growth of poxviruses by preventing the cleavage of
precursor proteins and is effective against poxviruses in
high doses (100 µg/ml), which makes its clinical use
rather unlikely [34].
For more than 25 years, VACV has been included in the
panel of viruses that are evaluated for their susceptibility
to a large variety of different classes of compounds. This
search has yielded a wealth of substances, lead com-
pounds and approaches that have proved effective against
VACV [35]. Most of the compounds that have been iden-
tified as anti-VACV agents are nucleoside analogs that fall
into different categories [36]. The above-mentioned
methiazone belongs to the thiosemicarbazones. Ribavi-
rin, an antiviral drug which is active against a number of
DNA and RNA viruses including VACV, belongs to the
IMP dehydrogenase inhibitors. There are numerous other
nucleoside or nucleotide analogs that have been reported
to have antiviral activity against VACV in vitro, such as
SAH hydrolase (S-adenosylhomocysteine hydrolase)
inhibitors, orotidine-5'-monophosphate (OMP) decar-
boxylase/cytidine triphosphate (CTP) synthetase inhibi-
tors and thydidylate synthase inhibitors. All these
compounds inhibit VACV replication in vitro and some of
the SAH hydrolase inhibitors suppress the consequences
of a VACV infection in vivo [37].
The only antiviral agent currently approved for use against
orthopoxviruses is cidofovir (CDV-Vistide), which
belongs to the acyclic nucleoside phosphonates. Cidofo-
vir is currently licensed for the treatment of cytomegalovi-
rus (CMV) retinitis and is thought to act by inhibiting the
cytomegalovirus DNA polymerase, a target shared with
the poxviruses. It has demonstrated antiviral activity
against poxviruses in vitro, and against cowpox and vac-
cinia viruses in mice [38,19,39]. It is also thought to
inhibit the activity of the proofreading exonuclease, lead-
ing to error-prone DNA synthesis during poxvirus replica-
tion [4]. However, its use for the treatment of VACV
adverse reactions is restricted under an investigational
new drug (IND) protocol. Under the IND, cidofovir can
only be used when VIG (vaccinia immune globulin) is not
efficacious. Renal toxicity is a known adverse reaction of
this drug. In recent years a bioavailable variant of orally
available cidofovir has been developed: HDP-cidofovirVirology Journal 2007, 4:8 http://www.virologyj.com/content/4/1/8
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(hexadecyloxypropyl-CDV) [40,41]. This modification
(adding a lipid) resulted in a new drug, which showed a
100-fold enhanced potency at blocking smallpox virus
reproduction in tissue-culture cells and might prove more
clinically relevant in the future [42,43].
Another nucleotide analog is adefovir [44]. However,
although adefovir shows significant in vitro antiviral activ-
ity against poxviruses, its efficacy as a therapeutic agent for
smallpox is currently uncertain. In addition to its activity
against VACV replication in tissue culture, it has a good
oral availability and has been approved for treatment of
Hepatitis B [45], making it a serious candidate. This com-
pound needs to be evaluated further for its activity against
monkeypox and variola viruses before its real potential is
known [46].
Drugs that target systemic spread
In the last two years, a novel class of anti-poxvirus drugs
has emerged. These compounds do not inhibit viral repli-
cation directly but rather reduce virus spread. They
decrease the release of EEV from cells, which is considered
to be the main mechanism for rapid spread of poxviruses
in the infected host. EEV are actively extruded from cells
by interaction with actin tails. Actin tail formation is reg-
ulated by phosphorylation of the viral protein A36 by the
cellular tyrosine kinase c-Src, which can also be activated
by the epidermal growth factor receptor (EGFR), a mem-
brane-anchored receptor tyrosine kinase. A36R is located
in the membrane surrounding the EEV and is required for
actin polymerization and virulence [47,48]. Therefore,
specific kinase inhibitors for either kinase are able to
inhibit spread of poxviruses and greatly increase animal
survival after VACV infection.
One of these drugs is Gleevec (also called STI-571, imat-
inib mesylate or Glivec), which was licensed for use in
chronic myeloid leukemia and is approved for use in
humans. Gleevec inhibits Abl-family tyrosine kinases and,
to some extent, EGFR, and has been shown to block the
egress of VACV from infected cells [49,50]. Gleevec is not
the first example of poxvirus inhibition by a kinase inhib-
itor, but it is the first kinase-targeted drug approved for
use in humans that exhibits antiviral properties. The Erk
inhibitor U1026 blocks VACV replication in cultured cells
[51] and CI-1033, an EGFR kinase inhibitor, has similar
effects to Gleevec and is also able to rescue mice from a
lethal intranasal VACV challenge infection [50]. Poxvi-
ruses encode a growth factor (VGF) which has high
homology to EGF. These EGF-like growth factors are car-
ried by poxviruses to facilitate viral pathogenesis. VGF
binds to the EGFR and the effect of Cl-1033 is most likely
due to reduced EEV release which is normally triggered by
VGF. Two EGFR kinase inhibitors have obtained FDA
approval (gefitinib and erlotinib) and both drugs might
have anti-poxvirus properties.
A different type of drug is ST-246, which was identified by
high-throughput screening of a small-molecule com-
pound library for inhibitors of orthopoxvirus replication.
Its target is the F13L gene product, which is required for
production of extracellular virus. ST-246 also reduces
extracellular virus formation and, although it has little
effect on the production of intracellular virus, it can pro-
tect mice from lethal orthopoxvirus infection [50].
Further understanding of viral egress might identify novel
targets for intervention. The use of host cellular signaling
pathway blockades as antiviral chemotherapy has the
advantage that drug resistance cannot readily develop and
is highly promising. However, cellular targets always
require the consideration of unwanted side effects, which
have been described recently for kinase inhibitors [52].
Potential new drug targets
A large variety of gene products are essential or have
exactly defined functions in the viral replication cycle.
This knowledge can be exploited for the precise design of
drugs targeting these proteins [46]. Proteins with enzy-
matic activity, such as kinases or phosphatases, are espe-
cially good drug targets, because inhibitors might be easily
identified by high-throughput screens.
For example, the H6R gene encodes the viral topoisomer-
ase 1B (vTOPO), which is essential for DNA processing. It
shares extensive structural and mechanistic features with
the human type 1B enzyme (hTOPO). However, despite
these similarities, there are sufficient differences to allow
selective targeting of the viral variant. Two coumarin
drugs (novobiocin and coumermycin) are potent inhibi-
tors of vTOPO, which show little effect on hTOPO [53].
These early findings indicate that it is possible to discover
compounds that interact selectively with these enzymes.
Bond et al. [54] performed a high-throughput screen
which resulted in the identification of a different class of
small-molecule inhibitors that potently inhibit DNA
supercoil relaxation by vTOPO, and obtained promising
results for the therapeutic use of these compounds.
In addition, there are some protein kinases with defined
biochemical activity but unclear functions in viral replica-
tion. Kinases are the most frequently used drug targets,
and inhibitors with high specificity have been identified
for a multitude of cellular kinases [55]. Variola and vac-
cinia viruses encode two essential protein kinases with
well characterized kinase activity [56,57] – the VACV pro-
tein kinases 1 and 2 (VPK1 and VPK2). VPK1 is the B1R
kinase [56]. The H5R gene product in VACV is a natural
substrate of this enzyme [58], and both the H5 and B1Virology Journal 2007, 4:8 http://www.virologyj.com/content/4/1/8
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proteins are present in virions [58]. The B1 protein seems
to be involved in viral DNA synthesis ([59], as mutants
with temperature sensitive (ts) defects in B1 fail to synthe-
size viral DNA [57], but it is unclear how this protein func-
tions in this process or in phosphorylation of H5R. A
specific inhibitor of B1R might be developed into an anti-
viral drug with an adequate safety profile.
The second protein kinase of interest, the VPK2, is the
F10L protein kinase. F10L is required for viral replication
and is the major kinase encapsidated in virions. The prod-
uct of this gene shows autophosphorylation activity [60],
but also appears to be involved in the phosphorylation of
the A17 protein, which is one of its natural substrates.
Mutant viruses with ts lesions in F10 appear to be arrested
at a very early stage in virion morphogenesis [61,62]. Both
kinases could be models for the design of specific inhibi-
tors as antiviral drugs with a clearly defined effect spec-
trum.
Other possible starting points for drug design are nucleo-
side and nucleotide kinases like, for example, J2R and
A48R. The thymidine kinase J2R and thymidylate kinase
A48R are not required for viral replication, but J2R is
thought to have an attenuating influence on viral replica-
tion  in vivo [63]. A number of drugs that have been
approved for the treatment of herpes virus infections are
active against VACV in vitro. Other compounds that have
been tested in phase II/III clinical trials for these infections
are also active against orthopoxviruses [64]. As all these
active compounds are closely related halogenated uracil
analogs or phosphate nucleotides, the current hypothesis
is that the effect of these nucleoside analogs on orthopox-
viruses is not limited by their ability to inhibit the VACV
DNA polymerase but by their ability to be phosphorylated
by the thymidine kinase J2R. Clearly, more research into
the substrate specificity of J2R is required to open the pos-
sibilities for finding highly active and non-toxic nucleo-
side analogs [46].
Another interesting candidate for drug target design could
be the protein phosphatase encoded by the H1L. H1L has
been shown to be essential for viral replication, as it has
not been possible to generate recombinant viruses with
deletions in this gene and recombinant viruses with
repressible expression of H1L show reduced replication
[65]. Designing drugs which target this essential protein
could stop viral spread throughout infected people.
The host range and pathogenicity of poxviruses result
from the interactions of virally encoded factors with the
host immune system. The limited host range of variola
virus is thought to relate largely to the unique association
of viral gene products with the countless host signaling
pathways. Interference with these factors might be a novel
approach to develop drugs that reduce or ablate variola
virus pathogenicity.
Conclusion
Currently there are no FDA approved drugs on the market
for the treatment of poxvirus infections, however kinases
inhibitors show very good anti-poxvirus activity as off-tar-
get effect and have the potential for clinical applications.
Essential viral gene products in the poxviral replication
cycle have been identified that are potential targets for
new drug development, but also more basic research is
required to identify essential viral enzymes or pathogenic-
ity factors, which will enable the development of more
effective and specific anti-poxvirus drugs. Hopefully, these
drugs will make poxviruses unattractive as bioweapons.
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